Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

October 13, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Generalized Anxiety Disorder
Interventions
DIETARY_SUPPLEMENT

Kava (240mg of kavalactones per day)

Kava 60 milligrams per tablet = 240mg of kavalactones per day

DIETARY_SUPPLEMENT

Placebo

Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.

Trial Locations (2)

3122

Centre for Human Psychopharmacology - Swinburne University, Melbourne

4006

Royal Brisbane & Women's Hospital, Brisbane

All Listed Sponsors
collaborator

Swinburne University of Technology

OTHER

collaborator

The University of Queensland

OTHER

lead

University of Melbourne

OTHER

NCT02219880 - Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial | Biotech Hunter | Biotech Hunter